| Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2014: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥10,790,000 (Direct Cost: ¥8,300,000、Indirect Cost: ¥2,490,000)
|
|---|
| Outline of Final Research Achievements |
In the Japanese multicenter study cohort (the 1st cohort of this project), predictive value of serum p2PSA-related indices and other clinicopathological features at the time of starting active surveillance (AS) for the pathological reclassification at 1 year re-biopsy were investigated. By multivariate logistic regression analysis, baseline %p2PSA and ‘Phi (the Prostate Health Index)’ were the only independent predictive factors for pathological upgrade at 1 year after AS commencement.
In the PRIAS-JAPAN study cohort (the 2nd cohort of this project), longitudinally stored frozen sera are under collection from patients who are newly enrolled at 25 institutions where the Institutional Review Board approved the accompanying study. The 1st analysis on the predictive value of %p2PSA and Phi for pathological reclassification is scheduled to be carried out after collection of sera from 200 patients (projected time: the end of 2015).
|
